Oncology | Phase III Developments | HONG KONG

Hutchison China MediTech

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Hong Kong

Post An Enquiry

Virtual Booth

Natural Products Expo

Participation Not Confirmed

Update your events

Chi-Med Highlights Clinical Data to be Presented at the Upcoming ESMO Virtual Congress 2020

Lead Product(s): Surufatinib

Therapeutic Area: Oncology Product Name: HMPL-012

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 24, 2020

Details:

New and updated analyses on the studies of surufatinib and fruquintinib will be presented at the upcoming European Society for Medical Oncology (ESMO) Virtual Congress 2020.

Hutchison China MediTech

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Hong Kong

Post An Enquiry

Virtual Booth

Natural Products Expo

Participation Not Confirmed

Update your events

Chi-Med Plans to Submit Marketing Authorization Application for Surufatinib Following Scientific Advice from EMA’s CHMP

Lead Product(s): Surufatinib

Therapeutic Area: Oncology Product Name: HMPL-012

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 10, 2020

Details:

Application is based on the scientific advice which the company got from the European Medicines Agency’s Committee for Medicinal Products for Human Use for surufatinib for the treatment of patients with advanced neuroendocrine tumors.

Hutchison China MediTech

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Hong Kong

Post An Enquiry

Virtual Booth

Natural Products Expo

Participation Not Confirmed

Update your events

Chi-Med and Lilly to Collaborate in Commercializing Elunate® in China

Lead Product(s): Fruquintinib

Therapeutic Area: Oncology Product Name: Elunate

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Eli Lilly

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration July 28, 2020

Details:

Under the terms of the 2020 Amendment, Lilly will maintain the exclusive commercialization rights, and as a consequence, will continue to consolidate the sales of Elunate® in China. Chi-Med will collaborate with Lilly in commercializing Elunate® across China.

Hutchison China MediTech

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Hong Kong

Post An Enquiry

Virtual Booth

Natural Products Expo

Participation Not Confirmed

Update your events

US FDA Grants Fast Track Status to Chi-Med’s Fruquintinib for Colorectal Cancer

Lead Product(s): Fruquintinib

Therapeutic Area: Oncology Product Name: HMPL-013

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 20, 2020

Details:

Fast Track Designation has been granted for the development of fruquintinib, for the treatment of patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.

Hutchison China MediTech

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Hong Kong

Post An Enquiry

Virtual Booth

Natural Products Expo

Participation Not Confirmed

Update your events

Chi-Med Announces the Continuation of Phase III FRUTIGA Study of Fruquintinib in Second-Line Gastric Cancer in China

Lead Product(s): Fruquintinib,Paclitaxel

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 04, 2020

Details:

FRUTIGA is a Phase III trial in China of fruquintinib in combination with paclitaxel (Taxol®) in the treatment of patients with advanced gastric adenocarcinoma or gastroesophageal junction (“GEJ”) adenocarcinoma who have progressed after first-line standard chemotherapy.